Toxicity Analysis of Infused Fluorouracil in Cancer Treatment
Author Information
Author(s): Tebbutt N C, Norman A R, Cunningham D, Allen M, Chau I, Oates J, Hill M
Primary Institution: Royal Marsden Hospital
Hypothesis
Can clinical, laboratory, and temporal factors predict the risk of toxicity in patients receiving infused fluorouracil therapy?
Conclusion
The study identifies specific factors that can help predict which patients are at higher risk of developing severe toxicities from infused fluorouracil.
Supporting Evidence
- Infused fluorouracil has a different toxicity profile compared to bolus schedules.
- Diarrhoea, stomatitis, and palmar-plantar erythema are the most common toxicities.
- Early grade 1 toxicities can predict the likelihood of developing more severe toxicities.
Takeaway
This study looked at how some patients react badly to a cancer drug called fluorouracil, and found ways to tell who might have problems before they happen.
Methodology
The study analyzed a large cohort of patients receiving infused fluorouracil, assessing their toxicity profiles and identifying risk factors through statistical methods.
Potential Biases
Potential biases may arise from the observational nature of the study and the reliance on a single institution's data.
Limitations
The study is limited to a single center and may not generalize to all patient populations.
Participant Demographics
{"total":1470,"male":833,"female":637,"median_age":64,"performance_status":{"0-1":1081,"2-3":364,"unknown":25},"treatment_type":{"adjuvant":339,"palliative":1131}}
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 0.985–0.994
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website